Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + Epoetin Alfa in MDS Anemia
NCT00053001Phase 2Completed
- Sponsor
- Reliant Medical Group
- Start
- Jun 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in myelodysplastic syndrome (MDS), sponsored by Reliant Medical Group. Primary endpoint: Clinical response. Started Jun 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00053001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053001.